KLRC3: A Potential Cancer Therapeutic (G3823)

Target Name: KLRC3

NCBI ID: G3823

KLRC3

KLRC3: A Potential Cancer Therapeutic

KLRC3 (Kirsten rat sarcoma viral oncogene homolog 3) is a gene that has been identified as a potential drug target or biomarker for the treatment of various diseases, including cancer. The gene is located on chromosome 6p21 and encodes a protein known as KLRC3.

KLRC3 is a transmembrane protein that is expressed in a variety of tissues, including the brain, spleen, and lungs. It is involved in the process of cell signaling, specifically in the regulation of cell adhesion and migration. KLRC3 has been shown to play a role in the development and progression of several types of cancer, including lung, breast, and ovarian cancer.

One of the key features of KLRC3 is its ability to interact with several different proteins, including the TGF-β1 receptor. TGF-β1 is a protein that plays a critical role in the regulation of cell growth, differentiation, and survival. It is known to be involved in the development of many diseases, including cancer.

Research has shown that KLRC3 can interact with TGF-β1 and that this interaction may be important for the development of cancer. Studies have also shown that inhibiting KLRC3 activity can lead to the inhibition of TGF-β1 signaling, which may have implications for the treatment of cancer.

Another potential mechanism by which KLRC3 may contribute to the development of cancer is its role in the regulation of cell apoptosis, or programmed cell death. Apoptosis is a natural process that helps to remove damaged or dysfunctional cells from the body, and it is important for the growth and development of tissues. However, in cancer cells, apoptosis may be disrupted, leading to the survival and proliferation of these cells.

Research has shown that KLRC3 is involved in the regulation of cell apoptosis in cancer cells. Studies have shown that KLRC3 can induce cell apoptosis in cancer cells, and that this effect is dependent on the TGF-β1 signaling pathway. This suggests that KLRC3 may be a useful target for the treatment of cancer by inhibiting TGF-β1 signaling and promoting cell apoptosis.

In addition to its role in the regulation of cell apoptosis, KLRC3 may also be involved in the regulation of cell signaling pathways that are important for cancer development. For example, KLRC3 has been shown to be involved in the regulation of the PI3K/Akt signaling pathway, which is involved in the regulation of cell signaling and survival.

Given the potential role of KLRC3 in the regulation of cell signaling and apoptosis, it is an attractive target for the development of new cancer therapies. Preclinical studies have shown that KLRC3 can be effectively inhibited in cancer cells, and that this inhibition can lead to the inhibition of TGF-β1 signaling and the inhibition of cell growth.

In conclusion, KLRC3 is a gene that has been identified as a potential drug target or biomarker for the treatment of cancer. Its interaction with the TGF-β1 receptor and its role in the regulation of cell apoptosis and signaling pathways suggest that it may be an attractive target for the development of new cancer therapies. Further research is needed to confirm these findings and to develop effective treatments for cancer.

Protein Name: Killer Cell Lectin Like Receptor C3

Functions: Plays a role as a receptor for the recognition of MHC class I HLA-E molecules by NK cells and some cytotoxic T-cells

The "KLRC3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about KLRC3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets